Fredun Pharmaceuticals Limited (BOM:539730)
India
· Delayed Price · Currency is INR 710.05
+8.55 (1.22%)
At close: May 5, 2025
Fredun Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Operating Revenue | 4,035 | 3,466 | 2,743 | 2,217 | 1,316 | 1,103 | Upgrade
|
| Other Revenue | 24.96 | 15.79 | 3.34 | 27.23 | 22.64 | 23.96 | Upgrade
|
| Revenue | 4,060 | 3,482 | 2,747 | 2,245 | 1,338 | 1,127 | Upgrade
|
| Revenue Growth (YoY) | -5.16% | 26.75% | 22.37% | 67.74% | 18.74% | 17.21% | Upgrade
|
| Cost of Revenue | 3,140 | 2,757 | 2,191 | 1,843 | 1,070 | 870.36 | Upgrade
|
| Gross Profit | 919.75 | 724.71 | 555.79 | 401.99 | 268 | 256.58 | Upgrade
|
| Selling, General & Admin | 384.23 | 344.89 | 278.02 | 252.54 | 177.37 | 174.48 | Upgrade
|
| Other Operating Expenses | 55.31 | -1.12 | -1.97 | 7.33 | -1.54 | -2.63 | Upgrade
|
| Operating Expenses | 481.1 | 381.73 | 304.14 | 284.58 | 195.88 | 190.64 | Upgrade
|
| Operating Income | 438.65 | 342.99 | 251.65 | 117.41 | 72.12 | 65.95 | Upgrade
|
| Interest Expense | -174.69 | -125.18 | -75.62 | -43.91 | -38.4 | -40.82 | Upgrade
|
| Interest & Investment Income | 0.14 | 0.14 | 0.23 | 0.06 | 0.25 | 0.68 | Upgrade
|
| Currency Exchange Gain (Loss) | 7.19 | 7.19 | 13.85 | 11.81 | 0.55 | 2.31 | Upgrade
|
| Other Non Operating Income (Expenses) | -10.62 | -10.62 | -15.94 | 0.64 | -2.46 | -3.16 | Upgrade
|
| EBT Excluding Unusual Items | 260.68 | 214.52 | 174.18 | 86 | 32.07 | 24.95 | Upgrade
|
| Other Unusual Items | - | - | - | - | -11.64 | - | Upgrade
|
| Pretax Income | 260.68 | 214.52 | 175.09 | 86 | 32.07 | 24.95 | Upgrade
|
| Income Tax Expense | 72.69 | 58.29 | 67.02 | 22.65 | 11.92 | 5.93 | Upgrade
|
| Net Income | 187.98 | 156.23 | 108.07 | 63.35 | 20.15 | 19.02 | Upgrade
|
| Net Income to Common | 187.98 | 156.23 | 108.07 | 63.35 | 20.15 | 19.02 | Upgrade
|
| Net Income Growth | 4.95% | 44.57% | 70.58% | 214.45% | 5.93% | -57.36% | Upgrade
|
| Shares Outstanding (Basic) | 5 | 5 | 4 | 4 | 4 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 5 | 4 | 4 | 4 | 4 | Upgrade
|
| Shares Change (YoY) | 0.86% | 3.66% | 7.85% | 4.06% | 0.01% | 3.67% | Upgrade
|
| EPS (Basic) | 40.35 | 33.66 | 24.13 | 15.26 | 5.05 | 4.77 | Upgrade
|
| EPS (Diluted) | 40.35 | 33.66 | 24.13 | 15.26 | 5.05 | 4.77 | Upgrade
|
| EPS Growth | 4.06% | 39.48% | 58.14% | 202.19% | 5.92% | -58.87% | Upgrade
|
| Free Cash Flow | - | -80.78 | -239.03 | -66.66 | -12.18 | -121.37 | Upgrade
|
| Free Cash Flow Per Share | - | -17.40 | -53.38 | -16.05 | -3.05 | -30.42 | Upgrade
|
| Dividend Per Share | - | 0.700 | 0.700 | 0.700 | 0.700 | 0.660 | Upgrade
|
| Dividend Growth | - | - | - | - | 6.06% | 1.54% | Upgrade
|
| Gross Margin | 22.66% | 20.82% | 20.23% | 17.91% | 20.03% | 22.77% | Upgrade
|
| Operating Margin | 10.80% | 9.85% | 9.16% | 5.23% | 5.39% | 5.85% | Upgrade
|
| Profit Margin | 4.63% | 4.49% | 3.93% | 2.82% | 1.51% | 1.69% | Upgrade
|
| Free Cash Flow Margin | - | -2.32% | -8.70% | -2.97% | -0.91% | -10.77% | Upgrade
|
| EBITDA | 483.4 | 380.41 | 279.3 | 138.74 | 91.94 | 84.61 | Upgrade
|
| EBITDA Margin | 11.91% | 10.93% | 10.17% | 6.18% | 6.87% | 7.51% | Upgrade
|
| D&A For EBITDA | 44.75 | 37.42 | 27.65 | 21.33 | 19.82 | 18.66 | Upgrade
|
| EBIT | 438.65 | 342.99 | 251.65 | 117.41 | 72.12 | 65.95 | Upgrade
|
| EBIT Margin | 10.80% | 9.85% | 9.16% | 5.23% | 5.39% | 5.85% | Upgrade
|
| Effective Tax Rate | 27.89% | 27.17% | 38.28% | 26.33% | 37.17% | 23.76% | Upgrade
|
| Revenue as Reported | 4,069 | 3,491 | 2,765 | 2,261 | 1,353 | 1,133 | Upgrade
|
| Advertising Expenses | - | 11 | 0.99 | 4.58 | 1.57 | 3.06 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.